Brunstatt, France

Henri Mattes

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 5.2

ph-index = 2

Forward Citations = 77(Granted Patents)


Location History:

  • Brunstatt, FR (2001 - 2013)
  • Michelbach le Bas, FR (2021 - 2022)

Company Filing History:


Years Active: 2001-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):

Title: The Innovative Journey of Henri Mattes

Introduction

Henri Mattes, an accomplished inventor based in Brunstatt, France, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 10 patents, he specializes in the development of innovative compounds focused on inhibiting NOD-like receptor protein 3 (NLRP3) inflammasome activity, an area of great importance in the treatment of various diseases and disorders.

Latest Patents

Among his latest inventions are novel thienopyrrolotriazinacetamide compounds that are specifically designed to inhibit NLRP3 inflammasome activity. The invention outlines the structural formula of these compounds and describes the processes for their preparation, pharmaceutical compositions, and possible medicinal applications in treating NLRP3-mediated conditions. Additionally, he has developed novel pyridazin-3-yl phenol compounds, similarly targeting NLRP3 inflammasome activity, further emphasizing his commitment to advancing medical science through innovation.

Career Highlights

Henri Mattes' work primarily takes place at Novartis AG, a leading pharmaceutical company known for its dedication to innovative health solutions. His research not only focuses on synthesizing new compounds but also emphasizes their medical applications and efficacy in treating serious health conditions.

Collaborations

In his innovative journey, Henri collaborates with notable coworkers such as Christopher Farady and Nina Gommermann. These partnerships strengthen his research efforts and contribute to the broader goal of advancing pharmaceutical developments.

Conclusion

With a proven track record of inventiveness and a robust portfolio of patents, Henri Mattes continues to play a crucial role in the pharmaceutical industry. His dedication to developing medications that target critical biological pathways illustrates his commitment to improving health outcomes through innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…